Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Peter N. LeSouëf is active.

Publication


Featured researches published by Peter N. LeSouëf.


The Journal of Pediatrics | 1999

Inhalation therapy in asthma: Nebulizer or pressurized metered-dose inhaler with holding chamber? In vivo comparison of lung deposition in children

Johannes H. Wildhaber; Nigel D. Dore; Joyce M. Wilson; Sunalene G. Devadason; Peter N. LeSouëf

OBJECTIVE To compare lung deposition from a nebulizer and a pressurized metered-dose inhaler (pMDI)/holding chamber to determine their efficiency in aerosol delivery to children. STUDY DESIGN Children with stable asthma (n = 17) aged 2 to 9 years inhaled in random order radiolabeled salbutamol from a nebulizer and a pMDI through a nonstatic holding chamber. Body and lung deposition of radiolabeled salbutamol was assessed with a gamma camera. RESULTS Mean (absolute dose) total lung deposition expressed as a percentage of the nebulized dose was 5.4% (108 microg) in younger children (<4 years) and 11.1% (222 microg) in older children (>4 years). Mean (absolute dose) total lung deposition expressed as a percentage of the metered dose was 5.4% (21.6 microg) in younger and 9.6% (38.4 microg) in older children. CONCLUSIONS For the same age groups we have shown equivalent percentages of total lung deposition of radiolabeled salbutamol aerosolized by either a nebulizer or a pMDI/holding chamber. However, the delivery rate per minute and the total dose of salbutamol deposited were significantly higher for the nebulizer.


Journal of Immunology | 2009

Interactions between Innate Antiviral and Atopic Immunoinflammatory Pathways Precipitate and Sustain Asthma Exacerbations in Children

Lily S. Subrata; Joelene Bizzintino; Emilie Mamessier; Anthony Bosco; Katherine Mckenna; Matthew E. Wikstrom; Jack Goldblatt; Peter D. Sly; Belinda J. Hales; Wayne R. Thomas; Ingrid A. Laing; Peter N. LeSouëf; Patrick G. Holt

Severe asthma exacerbations in children requiring hospitalization are typically associated with viral infection and occur almost exclusively among atopics, but the significance of these comorbidities is unknown. We hypothesized that underlying interactions between immunoinflammatory pathways related to responses to aeroallergen and virus are involved, and that evidence of these interactions is detectable in circulating cells during exacerbations. To address this hypothesis we used a genomics-based approach involving profiling of PBMC subpopulations collected during exacerbation vs convalescence by microarray and flow cytometry. We demonstrate that circulating T cells manifest the postactivated “exhausted” phenotype during exacerbations, whereas monocyte/dendritic cell populations display up-regulated CCR2 expression accompanied by phenotypic changes that have strong potential for enhancing local inflammation after their recruitment to the atopic lung. Notably, up-regulation of FcεR1, which is known to markedly amplify capacity for allergen uptake/presentation to Th2 effector cells via IgE-mediated allergen capture, and secondarily programming of IL-4/IL-13-dependent IL-13R+ alternatively activated macrophages that have been demonstrated in experimental settings to be a potent source of autocrine IL-13 production. We additionally show that this disease-associated activation profile can be reproduced in vitro by cytokine exposure of atopic monocytes, and furthermore that IFN-α can exert both positive and negative roles in the process. Our findings suggest that respiratory viral infection in atopic children may initiate an atopy-dependent cascade that amplifies and sustains airway inflammation initiated by innate antiviral immunity via harnessing underlying atopy-associated mechanisms. These interactions may account for the unique susceptibility of atopics to severe viral-induced asthma exacerbations.


Thorax | 1996

Effect of electrostatic charge, flow, delay and multiple actuations on the in vitro delivery of salbutamol from different small volume spacers for infants.

Johannes H. Wildhaber; Sunalene G. Devadason; Ernst Eber; M. J. Hayden; Mark L. Everard; Q. A. Summers; Peter N. LeSouëf

BACKGROUND: A study was undertaken to determine the influences of electrostatic charge, flow, delay, and multiple actuations on the in vitro delivery of salbutamol generated by a pressurised metered dose inhaler (pMDI) from small volume spacers used in infants. METHODS: Ten actuations from a salbutamol pMDI were drawn at different flow rates after either single or multiple actuations, with or without delay, through either static or reduced static spacers. An ionic detergent was used to reduce the charge of plastic spacers (Babyhaler, Babyspacer, Aerochamber, Nebuhaler). Electrostatic charge was measured using an electrometer. A multistage liquid impinger was used to determine the particle size distribution of the output of the pMDI through the spacers. RESULTS: Electrostatic charge on the surface of plastic spacers had the greatest influence on delivery, causing a decrease in drug delivery. Reducing charge by coating the surface with ionic detergent resulted in an increase of 46.5-71.1% (p < 0.001) in small (< 6.8 microns) particle delivery from small volume plastic spacers. Lower flow, delay, and multiple actuations resulted in decreased delivery from static spacers. Lower flow resulted in a decrease of 15% in small (< 9.6 microns) particle delivery. Delay and multiple actuations resulted in a decrease of 40.7% and 76.0%, respectively, in small (< 6.8 microns) particle delivery. The influences of lower flow, delay, and multiple actuations were greatly reduced or even eliminated by reducing charge. However, multiple actuations still resulted in a significant decreased delivery (p < 0.05). The reduced static Nebuhaler had a higher delivery than all small volume spacers. CONCLUSIONS: Electrostatic charge has a major influence on the delivery of salbutamol from small volume spacers. Using a metal spacer or ionic detergent coating of plastic spacers resulted in no or reduced charge and hence in improved delivery. Lower flow, delay, and multiple actuations played a major part only in static spacers.


Clinical & Experimental Allergy | 1998

Association of polymorphisms within the tumour necrosis factor (TNF) genes and childhood asthma

R.V. Albuquerque; Catherine M. Hayden; Lyle J. Palmer; Ingrid A. Laing; Peter J. Rye; Neil A. Gibson; Paul R. Burton; J. Goldblatt; Peter N. LeSouëf

Tumour necrosis factor alpha (TNFα) is a potent modulator of immune and inflammatory responses, and has been implicated in a variety of autoimmune diseases, including asthma. Increased levels of TNFα have been detected in both sputa and bronchoalveolar lavage fluid of asthmatic subjects during acute attacks. Interindividual variation in TNFα levels may be genetically determined and polymorphisms within the TNF genes and nearby HLA Class II region have been associated with differences in TNFα production. Objective To investigate the association of differences in asthma‐related phenotypes with two biallelic polymorphisms: a G to A substitution at position −308 of the TNFα gene promoter (TNF1 and TNF2 alleles) and an NcoI polymorphism in the first intron of the lymphotoxin alpha gene (LT‐α*1 and LT‐α*2 alleles).


Chest | 2008

Inhaled mannitol improves lung function in cystic fibrosis

Anna Jaques; Evangelia Daviskas; James A. Turton; Karen McKay; Peter Cooper; Robert G. Stirling; Colin F. Robertson; Peter Bye; Peter N. LeSouëf; Bruce Shadbolt; Sandra D. Anderson; Brett Charlton

BACKGROUND The airways in patients with cystic fibrosis (CF) are characterized by the accumulation of tenacious, dehydrated mucus that is a precursor for chronic infection, inflammation, and tissue destruction. The clearance of mucus is an integral component of daily therapy. Inhaled mannitol is an osmotic agent that increases the water content of the airway surface liquid, and improves the clearance of mucus with the potential to improve lung function and respiratory health. To this end, this study examined the efficacy and safety of therapy with inhaled mannitol over a 2-week period. METHODS This was a randomized, double-blind, placebo-controlled, crossover study. Thirty-nine subjects with mild-to-moderate CF lung disease inhaled 420 mg of mannitol or placebo twice daily for 2 weeks. Following a 2-week washout period, subjects were entered in the reciprocal treatment arm. Lung function, respiratory symptoms, quality of life, and safety were assessed. RESULTS Mannitol treatment increased FEV(1) from baseline by a mean of 7.0% (95% confidence interval [CI], 3.3 to 10.7) compared to placebo 0.3% (95% CI, - 3.4 to 4.0; p < 0.001). The absolute improvement with mannitol therapy was 121 mL (95% CI, 56.3 to 185.7), which was significantly more than that with placebo (0 mL; 95% CI, - 64.7 to 64.7). The forced expiratory flow in the middle half of the FVC increased by 15.5% (95% CI, - 6.5 to 24.6) compared to that with placebo (increase, 0.7%; 95% CI, - 8.3 to 9.7; p < 0.02). The safety profile of mannitol was adequate, and no serious adverse events related to treatment were observed. CONCLUSIONS Inhaled mannitol treatment over a period of 2 weeks significantly improved lung function in patients with CF. Mannitol therapy was safe and well tolerated. TRIAL REGISTRATION (ClinicalTrials.gov) Identifier: NCT00455130.


The Journal of Pediatrics | 1984

Total resistance of the respiratory system in preterm infants with and without an endotracheal tube

Peter N. LeSouëf; Sandra J. England; A. Charles Bryan

The passive compliance and resistance of the respiratory system were measured in 12 spontaneously breathing newborn infants before and after endotracheal extubation. End-inspiratory airway occlusions were used to relax the respiratory muscles, allowing occlusion pressure to be measured and respiratory system compliance and resistance to be calculated from the flow volume relationship of the subsequent passive expiration. Airway pressure was measured from an endotracheal tube or a face mask, expiratory flow from a pneumotachograph, and expiratory volume from the integrated flow signal. In six of the infants, diaphragmatic electromyography was also performed before and after extubation. Resistance and EMG findings were both decreased by extubation (mean decrease 43.9%, P less than 0.001 and 27.3%, P less than 0.05, respectively), but compliance was unchanged. Thus, by substantially increasing resistance, an endotracheal tube causes the diaphragm to increase its activity to maintain ventilation.


Pediatric Pulmonology | 2000

Parental factors affecting respiratory function during the first year of life

Sally Young; Duane L. Sherrill; Jacqueline Arnott; D. Diepeveen; Peter N. LeSouëf; Louis I. Landau

In a prospective, longitudinal, population‐based cohort study of familial and environmental influences on the development of wheezing respiratory illness in early childhood, we identified infant length, weight, gender, and exposure to maternal cigarette smoking as significant determinants of lung function during the first year of life. A cohort of 237 infants (106 females: 131 males) was evaluated, and 496 lung function measurements were made between the ages of 1–12 months. Respiratory function was assessed using the rapid thoracic compression technique to obtain maximum expiratory flow at functional residual capacity (V′maxFRC). Parental history of asthma and smoking habits during pregnancy were obtained by questionnaire. Data were analyzed using a longitudinal random effects model. Infants with a parental history of asthma and/or in utero passive smoke exposure were compared to a reference group of infants who had no parental history of asthma and in whom neither parent smoked pre‐ or postnatally.


European Respiratory Journal | 1996

Electrostatic charge on a plastic spacer device influences the delivery of salbutamol

Johannes H. Wildhaber; Sunalene G. Devadason; Mj Hayden; R James; Ap Dufty; Ra Fox; Qa Summers; Peter N. LeSouëf

The aim of this study was to determine whether electrostatic charge on a plastic spacer decreases the delivery of salbutamol from a pressurized metered-dose inhaler (pMDI) and, if so, to find an optimal and practical treatment to remove the charge. Ten single actuations from a salbutamol pMDI were drawn through different Volumatic spacers at a constant flow of 60 L.min-1. The efficacies of different methods of removing charge were tested, including detergent coating of the spacers. A multistage liquid impinger was used to determine the particle size distribution of the output of the pMDI through the Volumatic spacers. The electrostatic charge on the inner surface of the spacers was measured both quantitatively with an electrometer, and qualitatively by the attraction of a thin strip of cellulose membrane to the wall of the spacer. Each experiment was repeated four times. Ionic detergent coating of the spacers removed the charge for at least 24 h. This resulted in an increase of 55-70% in small particle (< 6.8 microns) delivery compared to delivery from new spacers with high charge. We have demonstrated that electrostatic charge plays a major role in the delivery of salbutamol through plastic spacers. Adequate treatment with ionic detergent removes the charge and improves drug delivery.


Pediatric Pulmonology | 1997

Aerosol delivery to wheezy infants: a comparison between a nebulizer and two small volume spacers.

Johannes H. Wildhaber; Sunalene G. Devadason; Mark J. Hayden; Ernst Eber; Quentin A. Summers; Peter N. LeSouëf

Inhalation therapy for wheezy infants with either a nebulizer or a pressurized metered‐dose inhaler (pMDI) through a spacer is common practice. The aim of our study was to compare aerosol delivery to wheezy infants from a nebulizer and from a pMDI via two small volume spacers. Twenty wheezy infants (aged 4–12 months) were recruited. They inhaled salbutamol from a Pari‐Baby® nebulizer, from a detergent‐coated Babyhaler®, and from a Nebuchamber® in random order. A filter was placed between the inhalation systems and the patients. The amount of salbutamol deposited on the filter was measured using an ultraviolet spectrophotometer and was expressed as a percentage of the total nebulized or actuated doses. The mean total nebulized dose for the Pari‐Baby® (1030 μg) was higher (P < 0.001) than the mean actuated dove from a pMDI for the Babyhaler® (374 μg) and for the Nebuchamber® (378 μg). Mean drug deposition on the filter was 40.2% (150 μg) of the total actuated dose for the detergent‐coated Babyhaler® and 40.7% (154 μg) of the total actuated dose for the Nebuchamber®. There was no significant difference in drug deposition on the filter between the two spacers. Mean drug deposition on the filter was 25.3% (260 μg) of the total nebulized dose for the Pari‐Baby® nebulizer. There was no weight dependence in drug deposition on the filter for the two spacers, but, drug deposition increased with the subjects weight for the nebulizer. We have shown that aerosol delivery to wheezy infants from a pMDI through small volume spacers is effective and that a higher percentage of the total amount of salbutamol is delivered than from a nebulizer. The weight dependence in drug deposition for the nebulizer can be of clinical relevance. Pediatr Pulmonol. 1997; 23:212–216


Clinical & Experimental Allergy | 1999

Polymorphisms in the β2‐adrenoreceptor gene are associated with decreased airway responsiveness

Ramsay Ce; Catherine M. Hayden; Katrina J. Tiller; Paul R. Burton; J. Goldblatt; Peter N. LeSouëf

There are a number of candidate genes thought to play a role in the development of asthma. Polymorphisms at amino acid positions 16 (arginine to glycine) and 27 (glutamine to glutamic acid) of the β2‐adrenoreceptor (B2AR) gene are known to be functionally relevant and have been associated with more severe forms of asthma, nocturnal asthma and decreased airway responsiveness in asthmatic subjects.

Collaboration


Dive into the Peter N. LeSouëf's collaboration.

Top Co-Authors

Avatar

Jack Goldblatt

University of Western Australia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Louis I. Landau

University of Western Australia

View shared research outputs
Top Co-Authors

Avatar

Ingrid A. Laing

University of Western Australia

View shared research outputs
Top Co-Authors

Avatar

Peter D. Sly

King Edward Memorial Hospital

View shared research outputs
Top Co-Authors

Avatar

Sunalene G. Devadason

University of Western Australia

View shared research outputs
Top Co-Authors

Avatar

Siew-Kim Khoo

University of Western Australia

View shared research outputs
Top Co-Authors

Avatar

Catherine M. Hayden

University of Western Australia

View shared research outputs
Top Co-Authors

Avatar

Johannes H. Wildhaber

Princess Margaret Hospital for Children

View shared research outputs
Top Co-Authors

Avatar

Debra J. Turner

Telethon Institute for Child Health Research

View shared research outputs
Researchain Logo
Decentralizing Knowledge